《大行報告》高盛:友邦(01299.HK)中期業績強勁 重申「買入」評級
高盛發表報告表示,友邦(01299.HK)中期業績強勁,新業務價值按實質匯率計按年升32%,按固定匯率計按年升37%,較該行預期高4%及3%,第二季新業務價值增速按年加快至44%(按實質匯率計),對比今年首季23%,五個主要市場均錄得增長,而受惠通關後內地訪客重臨令銷售強勁,本港業務成主要推動力。
該行指友邦在中國內地和內地訪港旅客(MCV)領域的保障產品銷售均呈現穩定增長,其中保障產品佔新業務的50%以上(按保單數量計算),相信有助解決投資者對中長期勢頭的擔憂。
高盛維持友邦「買入」投資評級及目標價101元。(wl/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.